Moldova: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis
Civil society organisations, communities affected by tuberculosis (TB), and partner institutions in Moldova sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve equitable access to the lifesaving TB drug bedaquiline in Moldova, and all other countries with a high burden of TB.
This letter follows letters with similar calls to J&J sent by Belarus’ national TB programme, Ukraine’s national TB programme, and TB activists and civil society from Azerbaijan, Ukraine, and around the world.
This letter was sent on 15 September 2023, after an announcement made by the Stop TB Partnership/Global Drug Facility (GDF) about a deal with J&J for access to generic bedaquiline to a limited number of countries. As of 21 September 2023, 11:30 AM CET, Moldova’s National TB Programme has not been included in the GDF/J&J deal.